As male birth control gets closer to reality, men are lining up for clinical trials - Scorecard - MDSpire

As male birth control gets closer to reality, men are lining up for clinical trials

  • By

  • Annalisa Merelli

  • February 2, 2026

  • 0 min

Share

Clinical Scorecard: Men Eagerly Participate in Clinical Trials as Male Contraceptive Options Advance

At a Glance

CategoryDetail
ConditionMale Contraception
Key MechanismsHormonal and non-hormonal methods to reduce sperm production or create temporary vasectomy-like effects.
Target PopulationMen seeking contraceptive options, particularly in response to changing reproductive rights landscape.
Care SettingClinical trials and research settings.

Key Highlights

  • 61% of men globally are open to trying male contraceptives.
  • Three male contraceptive products are nearing commercialization.
  • Men are actively signing up for clinical trials, with over 20,000 registrants for future studies.
  • Interest in male contraception has surged post-Dobbs decision.
  • Men's motivations include supporting partners and personal reproductive choices.

Guideline-Based Recommendations

Diagnosis

  • Assess male interest and willingness to participate in contraceptive trials.

Management

  • Encourage participation in clinical trials for emerging male contraceptive methods.

Monitoring & Follow-up

  • Track sperm count and side effects during trial phases.

Risks

  • Potential skin burns from thermal methods and hormonal side effects.

Patient & Prescribing Data

Men from diverse backgrounds interested in contraceptive options.

Emerging products include hormonal gels and non-hormonal pills, with varying mechanisms of action.

Clinical Best Practices

  • Facilitate access to information about ongoing clinical trials.
  • Engage men in discussions about reproductive health responsibilities.
  • Monitor societal attitudes towards male contraception to inform outreach efforts.

References

Original Source(s)

As male birth control gets closer to reality, men are lining up for clinical trials

  • by Annalisa Merelli

  • February 2, 2026

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

The Hidden Differences Between Oral Contraceptives

National adverse-event and prescribing data suggest oral contraceptive formulations differ in reported acne, migraine, anxiety, and depression 

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.